DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR AKYNZEO
All Clinical Trials for Akynzeo
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03008213 | Combination of Netupitant and Palonosetron (Akynzeo®) in the Treatment of Refractory CINV | Terminated | University of California, San Diego | Phase 2 | 2017-01-01 | Prevention and control of Chemotherapy-Induced Nausea and Vomiting (CINV) are most important in treatment of cancer patients. CINV is one of the most distressing severe side effects of cancer treatment and can have a significant impact on a patient's quality of life. The chemotherapy agents that cause the worst degree of nausea and vomiting are categorized into two groups: moderately emetogenic chemotherapy (MEC) and highly emetogenic chemotherapy (HEC). Nausea and vomiting that occurs within the first day of the administration of chemotherapy agents is considered acute CINV, while nausea and vomiting following 24 hours of the administration of chemotherapy agents is considered delayed CINV. Refractory CINV occurs when patients develop CINV during subsequent cycles of chemotherapy when drugs preventing vomiting and nausea (antiemetic prophylaxis) has not been successful in controlling CINV in earlier cycles. The purpose of this study is to assess the efficacy of Akynzeo in the treatment of refractory CINV |
| NCT03040726 | Netupitant and Palonosetron (AKYNZEO) for Chronic Nausea and Vomiting in Cancer Patients | Not yet recruiting | Helsinn Healthcare SA | Phase 2/Phase 3 | 2017-06-01 | The goal of this clinical research study is to learn if netupitant/palonosetron can help to decrease chronic nausea and vomiting in patients with cancer. The safety of the study drug will also be studied. Some participants will receive the study drug and some will receive a placebo. A placebo is not a drug. It looks like the study drug but is not designed to treat any disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect. |
| NCT03040726 | Netupitant and Palonosetron (AKYNZEO) for Chronic Nausea and Vomiting in Cancer Patients | Not yet recruiting | M.D. Anderson Cancer Center | Phase 2/Phase 3 | 2017-06-01 | The goal of this clinical research study is to learn if netupitant/palonosetron can help to decrease chronic nausea and vomiting in patients with cancer. The safety of the study drug will also be studied. Some participants will receive the study drug and some will receive a placebo. A placebo is not a drug. It looks like the study drug but is not designed to treat any disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect. |
| NCT03403712 | A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cance | Recruiting | George Clinical Pty Ltd | Phase 3 | 2018-03-16 | Multicenter, randomized, double-blind, double-dummy, parallel group, stratified study assessing the safety and describing the efficacy of a single dose of intraveneous (IV) fosnetupitant/palonosetron (260 mg/0.25 mg) infusion [test] versus oral netupitant/palonosetron (300 mg/0.5 mg) combination [control]; each administered with oral dexamethasone prior to initial and repeated cycles of AC chemotherapy in female breast cancer patients. |
| NCT03403712 | A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cance | Recruiting | PSI CRO AG | Phase 3 | 2018-03-16 | Multicenter, randomized, double-blind, double-dummy, parallel group, stratified study assessing the safety and describing the efficacy of a single dose of intraveneous (IV) fosnetupitant/palonosetron (260 mg/0.25 mg) infusion [test] versus oral netupitant/palonosetron (300 mg/0.5 mg) combination [control]; each administered with oral dexamethasone prior to initial and repeated cycles of AC chemotherapy in female breast cancer patients. |
| NCT03403712 | A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cance | Recruiting | Helsinn Healthcare SA | Phase 3 | 2018-03-16 | Multicenter, randomized, double-blind, double-dummy, parallel group, stratified study assessing the safety and describing the efficacy of a single dose of intraveneous (IV) fosnetupitant/palonosetron (260 mg/0.25 mg) infusion [test] versus oral netupitant/palonosetron (300 mg/0.5 mg) combination [control]; each administered with oral dexamethasone prior to initial and repeated cycles of AC chemotherapy in female breast cancer patients. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Akynzeo
Condition Name
Clinical Trial Locations for Akynzeo
Trials by Country
Clinical Trial Progress for Akynzeo
Clinical Trial Phase
Clinical Trial Sponsors for Akynzeo
Sponsor Name
